Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses (Q42200165)

18 October 2017

Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses (English)

1 reference

18 October 2017

Diana F Florescu

1

1 reference

PubMed ID

25120093

18 October 2017

Megan A Keck

series ordinal

2

1 reference

18 October 2017

13 August 2014

1 reference

Expert Review of Anti-infective Therapy

18 October 2017

1 reference

18 October 2017

12

1 reference

18 October 2017

1171-1178

1 reference

18 October 2017

10

1 reference

The eradication of smallpox--an overview of the past, present, and future

18 October 2017

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Diagnosis and management of smallpox

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Smallpox research activities: U.S. interagency collaboration, 2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

FDA Experience with Medical Countermeasures under the Animal Rule

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Ectromelia virus infections of mice as a model to support the licensure of anti-orthopoxvirus therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Treatment of Vaccinia and Cowpox Virus Infections in Mice with CMX001 and ST-246.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Emergence of cowpox: study of the virulence of clinical strains and evaluation of antivirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Development of CMX001 for the Treatment of Poxvirus Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Synthesis and early development of hexadecyloxypropylcidofovir: an oral antipoxvirus nucleoside phosphonate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Dynamics of cytomegalovirus populations harbouring mutations in genes UL54 and UL97 in a haematopoietic stem cell transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Human cytomegalovirus infection of placental cytotrophoblasts in vitro and in utero: implications for transmission and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Species-specific in vitro synthesis of DNA containing the polyoma virus origin of replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Reconstitution of simian virus 40 DNA replication with purified proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

1-O-hexadecyloxypropyl cidofovir (CMX001) effectively inhibits polyomavirus BK replication in primary human renal tubular epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Hexadecyloxypropyl-cidofovir (CMX001) suppresses JC virus replication in human fetal brain SVG cell cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

CMX001 (1-O-hexadecyloxypropyl-cidofovir) inhibits polyomavirus JC replication in human brain progenitor-derived astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

A case of progressive multifocal leukoencephalopathy and idiopathic CD4+ lymphocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

Detection of molluscum contagiosum virus (MCV) DNA in the plasma of an immunocompromised patient and possible reduction of MCV DNA with CMX-001

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.948847

10.1586/14787210.2014.948847

21 January 2018

Identifiers

DOI

1 reference

18 October 2017

1 reference

PubMed ID

25120093